1056382-25-2

Basic information

• Product Name: 4-Fluoro-4-phenylpiperidine hydrochloride
• Synonyms: 4-Fluoro-4-phenylpiperidine hydrochloride;4-Fluoro-4-(3-phenylpropyl)piperidine hydrochloride
• CAS NO: 1056382-25-2
• Molecular Formula: C₁₁H₁₄FN*ClH
• Molecular Weight: 215.6949032
• Mol File: 1056382-25-2.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-Fluoro-4-phenylpiperidine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Fluoro-4-phenylpiperidine hydrochloride(1056382-25-2)
• EPA Substance Registry System: 4-Fluoro-4-phenylpiperidine hydrochloride(1056382-25-2)

Safety Data

• Hazardous Substances Data: 1056382-25-2(Hazardous Substances Data)

Upstream product

• 400770-90-3 tert‐butyl‐4‐fluoro‐4‐phenylpiperidine‐1‐carboxylate 

Downstream Products

• 1127499-92-6 1'-butyl-4-fluoro-4-phenyl-3,4,5,6-tetrahydro-2H,1'H-[1,4']bipyridinyl-2-one 
• 1254981-22-0 (3'-chloro-4-fluoro-4-phenyl-3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-2'-yl)hydrazine 
• 1254977-46-2 3-cyclopropylmethyl-7-(4-fluoro-4-phenyl-1-piperidinyl)-8-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyridine 
• 1254977-47-3 8-chloro-7-(4-fluoro-4-phenyl-1-piperidinyl)-3-(2,2,2-trifluoroethyl)-1,2,4-triazolo[4,3-a]pyridine 
• 1254979-91-3 8-(trifluoromethyl)-3-(cyclopropylmethyl)-7-[(4-phenyl-4-fluoro-1-piperidinyl)methyl]-[1,2,4]triazolo[4,3-a]pyridine 
• 1254981-31-1 2'-chloro-4-fluoro-4-phenyl-3'-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl 
• 1152617-71-4 2',3'-dichloro-4-fluoro-4-phenyl-3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl 

Relevant articles and documents

1',3'-DISUBSTITUTED-4-PHENYL-3,4,5,6-TETRAHYDRO-2H, 1'H-[1, 4'] BIPYRIDINYL-2'-ONES

The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors - subtype 2 ("mGluR2") which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.